[ad_1]
Merck announced on Thursday that its experimental treatment for respiratory syncytial virus (RSV) in infants showed positive results in a mid- to late-stage trial, bringing the company closer to seeking approval for the shot. The potential new competitor in the RSV treatment market witnessed significant reductions in RSV-related hospitalizations and lower respiratory infections compared to a placebo among infants. The trial results point towards a promising new option for infants affected by the virus. Merck aims to make the treatment available for infants as early as the 2025 to 2026 RSV season. The treatment, clesrovimab, demonstrated its effectiveness in reducing RSV-related hospitalizations and lower respiratory infections, making it a valuable new treatment option if approved. Results from the trial were consistent through both the five-month and six-month time points, with comparable rates of adverse and serious side effects between patients who received the treatment and those who took placebos. Dr. Octavio Ramilo expressed optimism about the results, highlighting the potential of clesrovimab to alleviate the burden of RSV on infants and their families. Merck’s clesrovimab could potentially compete against similar treatments from Sanofi and AstraZeneca, but with the added benefit of being administered regardless of infant weight, offering convenience in dosing.
[ad_2]
SOURCE
Emily Jensen, graduated from the London School of Economics and Political Science (LSE) in the UK in 2015 with a degree in Economics. She specializes in financial markets and international trade. After graduating, she worked as an analyst at an investment bank in London, where she developed expertise in global economic trends. She later transitioned into consulting, focusing on fintech ventures and providing insights into global economic developments. Emily is passionate about the intersection of finance and technology and aims to drive innovation in the financial sector.
